Rosetta Genomics to Present at the 25th Annual Roth Conference

        Rosetta Genomics to Present at the 25th Annual Roth Conference

PR Newswire

PHILADELPHIA and REHOVOT, Israel, March 12, 2013

PHILADELPHIA and REHOVOT, Israel, March 12, 2013 /PRNewswire/ -- Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, today announced that Ken Berlin,
President and Chief Executive Officer of the Company, will present a corporate
overview at the 25th Annual Roth Conference taking place from March 17-20,
2013 at the Ritz-Carlton Laguna Niguel in California. Mr. Berlin's
presentation will take place on Tuesday, March 19^th at 4:30 p.m. Pacific
time.

The presentation will be webcast live and archived online at the Investors
section of the Company's website at www.rosettagenomics.com.

The Annual Roth Conference, one of the largest of its kind in the U.S.,
features presentations from hundreds of growth companies, Q&A sessions, expert
panels and thousands of management one-on-one/small group meetings. This event
is designed to provide investors with a unique opportunity to gain insight
into emerging growth companies across a variety of sectors, including Business
Services, Consumer, Cleantech, Industrials & Resources, Healthcare, Metals &
Mining and Technology & Media.

About miRview^® Products
miRview^® are a series of microRNA-based diagnostic products offered by
Rosetta Genomics. miRview^® mets^2 accurately identifies the primary tumor
type in primary and metastatic cancer including CUP. miRview^®meso diagnoses
mesothelioma, a cancer connected to asbestos exposure. miRview^® lung
accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. miRview^® tests are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets^2 test, 60,000 from miRview^®meso, 54,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit www.mirviewdx.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating
toRosetta'sstrategic plan,the market acceptance of Rosetta's
miRview^®assays,particularly miRview^®mets^2,Rosetta's capitalization of
its microRNA platform, Rosetta's patent positionand Rosetta's development of
personalized medicine productsconstitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various important factors,
including those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011as
filed with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not be relied
upon as representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless required
by law.

Company Contact:                          Investor Contacts:
Rosetta Genomics           LHA
Ken Berlin, President & CEO Anne Marie Fields
(215) 382-9000, ext. 326    (212) 838-3777
investors@rosettagenomics.com         afields@lhai.com
                                                      or
                                                      Bruce Voss
                                                      (310) 691-7100
                                                      bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.

Website: http://www.rosettagenomics.com
 
Press spacebar to pause and continue. Press esc to stop.